Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06685835 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Insmed Incorporated.
- Active
- Registry status
- Phase 2
- Development phase
- 214
- Enrollment target
- 20
- Study locations
NCT06685835: Active Phase 2 study of Hidradenitis Suppurativa, sponsored by Insmed Incorporated.
NCT06685835 is a Phase 2 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Insmed Incorporated. The registered enrollment target is 214 participants, below the 594-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06685835, a Phase 2 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Insmed Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 214 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brensocatib
Study Locations (20)
Florida
- USA026 - Coral Gables
- USA027 - Hollywood
- USA021 - Margate
- USA018 - Miami
- USA025 - Ocala
- USA004 - Tampa
- USA010 - Weston
Georgia
- USA028 - Atlanta
- USA011 - Sandy Springs
Michigan
- USA012 - Detroit
- USA024 - Fort Gratiot
Arizona
- USA001 - Phoenix
California
- USA007 - Sacramento
Indiana
- USA003 - Plainfield
Louisiana
- USA002 - Baton Rouge
Massachusetts
- USA017 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2026-11-17 |
| Phase | Phase 2 |
What the registry record for NCT06685835 still lists
NCT06685835 is an interventional study that assigns participants to a tested intervention. The registered 214 participants enrollment target is mid-sized for trials with a published cap, below the 594-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06685835 names 20 study sites across 12 states, led by Florida, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT06685835 about?
NCT06685835 is a clinical study titled "A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)". The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
What is the current status of trial NCT06685835?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2024-12-16. Estimated completion is 2026-11-17.
What conditions does trial NCT06685835 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06685835?
The interventions under investigation include: Placebo (DRUG), Brensocatib (DRUG).
Who is sponsoring clinical trial NCT06685835?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06685835 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06685835's enrollment target sits among peer trials
214 21st of 52 higher than 32 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- NCT04421248 · 214 participants · Phase 4
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
- NCT04667520 · 214 participants · NA
Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment
- NCT05418868 · 214 participants · Phase 1
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI